甘草酸镁联合丁二磺酸腺苷蛋氨酸治疗药物性肝损伤患者疗效研究

doi:10.3969/j.issn.1672-5069.2021.02.021

摘要/Abstract

摘要： 目的观察应用异甘草酸镁联合丁二磺酸腺苷蛋氨酸治疗药物性肝损伤(DILI)患者的疗效及血清血红素单加氧酶1(HO-1)、核因子E2相关因子2(Nrf-2)和谷胱甘肽过氧化物酶(GSH-Px)水平的变化。方法 2018年1月~2019年12月我院收治的78例DILI患者,采用随机数字表法将患者分为对照组和联合组,各39例。给予对照组丁二磺酸腺苷蛋氨酸静脉滴注,联合组在此治疗的基础上予以异甘草酸镁注射液静脉滴注,两组均连续治疗2 w。采用免疫荧光法检测血清Nrf-2,采用ELISA法检测血清肿瘤坏死因子α(TNF-α)、白介素-10(IL-10)、一氧化氮(NO)、一氧化氮合成酶(NOS)、HO-1、GSH-Px和巨噬细胞移动抑制因子(MIF)水平。结果在治疗2周结束时,联合组血清丙氨酸氨基转移酶水平为(65.9±7.7)U/L,天门冬氨酸氨基转移酶水平为(58.5±7.3)U/L,血清总胆红素水平为(20.5±5.3)μmol/L,均显著低于对照组【分别为(93.5±11.2)U/L、(91.3±10.8)U/L和(25.2±7.9)μmol/L,P<0.05】;血清一氧化氮合酶水平为(47.7±5.8)U/mg,GSH-Px水平为(0.8±0.1)ng/mL,显著高于对照组【分别为(38.5±5.6)U/mg和(0.5±0.1)U/mg,P<0.05】,而血清HO-1水平为(0.4±0.1)ng/mL,Nrf-2水平为(0.5±0.1)ng/mL, 显著低于对照组【分别为(0.7±0.1)ng/mL和(0.8±0.1)U/mg,P<0.05】;血清肿瘤坏死因子α水平为(3.0±0.5)ng/mL,MIF水平为(8.9±1.1)ng/mL,显著低于对照组【分别为(4.2±0.6)ng/mL和(11.4±1.5)ng/mL,P<0.05】,而血清血清白介素-10水平为(33.1±4.4)pg/mL,NO水平为(66.5±7.3)μmol/L,显著高于对照组【分别为(22.5±2.9)pg/mL和(41.1±5.6)μmol/L,P<0.05】。结论应用异甘草酸镁联合丁二磺酸腺苷蛋氨酸治疗DILI患者疗效较好,可能与其抑制了炎症反应,提高了抗氧化能力有关。

关键词: 药物性肝损伤, 异甘草酸镁, 丁二磺酸腺苷蛋氨酸, 血红素单加氧酶1, 核因子E2相关因子2, 谷胱甘肽过氧化物酶, 治疗

Abstract: Objective The aim of this study was to investigate the short-term efficacy of magnesium isoglycyrrhizinate and adenosylmethionine butanedisulfonate combination in treatment of patients with drug-induced liver injury (DILI) and serum heme monooxygenase 1(HO-1), nuclear factor E2 related factor 2(Nrf-2) and glutathione peroxidase (GSH-Px) level changes.Methods 78 patients with DILI were enrolled in this study between January 2018 and December 2019, and were randomly divided into control and combination groups, with 39 cases in each group. The patients in control group received intravenous infusion of adenosylmethionine butanedisulfonate, and those in the combination received intravenous infusion of magnesium isoglycyrrhizinate at the base of medicine in the control for two weeks. Serum Nrf-2, TNF-α, IL-10, NO, NOS, HO-1, GSH-Px and macrophage dectected.Results At the end two week migration inhibitory factor (MIF) were of treatment, serum alanine aminotransaminase level in the combination group was (65.9±7.7)U/L, serum AST level was (58.5±7.3)U/L, and serum total bilirubin level was (20.5±5.3)μmol/L, all significantly lower than 【(93.5±11.2)U/L, (91.3±10.8)U/L and (25.2±7.9)μmol/L, respectively, P<0.05】 in the control; serum NOS level was (47.7±5.8)U/mg, and serum GSH-Px level was (0.8±0.1)ng/mL, both significantly higher than 【(38.5±5.6)U/mg and (0.5±0.1)U/mg, respectively, P<0.05】, while serum HO-1 level was (0.4±0.1)ng/mL, and serum Nrf-2 level was (0.5±0.1)ng/mL, both significantly lower than 【(0.7±0.1)ng/mL and (0.8±0.1)U/mg, respectively, P<0.05】 in the control; serum TNF-α level was (3.0±0.5)ng/mL, and serum MIF level was (8.9±1.1)ng/mL, significantly lower than 【(4.2±0.6)ng/mL and (11.4±1.5)ng/mL, respectively, P<0.05】, while serum IL-10 level was (33.1±4.4)pg/mL, and serum NO level was (66.5±7.3)μmol/L, significantly higher than 【(22.5±2.9)pg/mL and (41.1±5.6)μmol/L, respectively, P<0.05】 in the control. Conclusion The magnesium isoglycyrrhizinate and adenosylmethionine butanedisulfonate combination in the treatment of patients with DILI have a short-term efficacy, which might be related to the inhibition of inflammatory and oxidative stress reactions, and needs further clinical investigation.

Key words: Drug-induced liver injury, Magnesium isoglycyrrhizinate, Adenosylmethionine butanedisulfonate, Heme monooxygenase 1, Nuclear factor E2 related factor 2, Glutathione peroxidase, Therapy

林成, 王同彪, 李岳勇, 李龙华. 甘草酸镁联合丁二磺酸腺苷蛋氨酸治疗药物性肝损伤患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(2): 232-235.

Lin Cheng, Wang Tongbiao, Li Yueyong, et al. Short-term efficacy of magnesium isoglycyrrhizinate and adenosylmethionine butanedisulfonate combination in treatment of patients with drug-induced liver injury[J]. Journal of Practical Hepatology, 2021, 24(2): 232-235.

参考文献

[1] Yang ZB, Chen WW, Chen HP,et al. Mir-155 aggravated septic liver injury by oxidative stress-mediated er stress and mitochondrial dysfunction via targeting Nrf-2. Exp Mol Pathol, 2018, 105(3):387-394.
[2] Bessone F, Robles-Diaz M, Hernandez N,et al. Assessment of serious acute and chronic idiosyncratic drug-induced liver injury in clinical practice. Semin Liver Dis, 2019, 39(3):381-394.
[3] Grégoire S, Millecamps M, Naso L,et al. Therapeutic benefits of the methyl donor S-adenosylmethionine on nerve injury- induced mechanical hypersensitivity and cognitive impairment in mice. Pain, 2017, 158(5):802-810.
[4] Chen C, Liu YH, Cheng SB, et al. The hepatoprotective effects of XCHD and MgIG against methotrexate-induced liver injury and inflammation in rats through suppressing the activation of aim2 inflammasomes. Pathol Res Pract, 2020, 216(4):152875-152875.
[5] 于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南. 实用肝脏病杂志, 2017, 20(2):257-274.
[6] 中华医学会消化病学分会肝胆疾病协作组. 急性药物性肝损伤诊治建议(草案). 中华消化杂志, 2007, 27(11): 765-767.
[7] Teschke R. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the roussel uclaf causality assessment method. Expert Opin Drug Metab Toxicol, 2018, 14(11):1169-1187.
[8] Kleiner DE. Drug-induced liver injury:The hepatic pathologist's approach. Gastroenterol Clin North Am, 2017, 46(2):273-296.
[9] Xu Q, Wang J, Chen F,et al. Protective role of magnesium isoglycyrrhizinate in non-alcoholic fatty liver disease and the associated molecular mechanisms. Int J Mol Med, 2016, 38(1):275-282.
[10] Kim SH, Oh DS, Oh JY,et al. Silymarin prevents restraint stress-induced acute liver injury by ameliorating oxidative stress and reducing inflammatory response. Molecules, 2016, 21(4):443-443.
[11] Zou X, Wang Y, Peng C,et al. Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatin induced model of liver injury. Int J Mol Med, 2018, 42(4):2020-2030.
[12] Howell LS, Ireland L, Park BK, et al. Mir-122 and other micrornas as potential circulating biomarkers of drug-induced liver injury. Expert Rev Mol Diagn, 2018, 18(1):47-54.
[13] 朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响. 实用肝脏病杂志, 2019, 22(6): 872-875.
[14] Zhang W, Li F, Ye Y,et al. Isoglycyrrhizinate magnesium enhances hepatoprotective effect of FK506 on ischemia-reperfusion injury through HMGB1 inhibition in a rat model of liver transplantation. Transplantation, 2017, 101(12):2862-2872.
[15] Jiang W, Liu J, Li P,et al. Magnesium isoglycyrrhizinate shows hepatoprotective effects in a cyclophosphamide-induced model of hepatic injury. Oncotarget, 2017, 8(20):33252-33264.
[16] 樊沛, 鱼宁彬. 异甘草酸镁联合多烯磷酯酰胆碱治疗对慢性乙型肝炎患者血清细胞因子的影响和疗效观察. 实用肝脏病杂志, 2017, 20(3): 276-279.
[17] Zhou RJ, Ye H, Wang F,et al. Apigenin inhibits D-galactosamine/LPS-induced liver injury through upregulation of hepatic Nrf-2 and PPARγ expressions in mice. Biochem Biophys Res Commun, 2017, 493(1):625-630.
[18] Abdel-Gaber SA, Geddawy A, Moussa RA. The hepatoprotective effect of sitagliptin against hepatic ischemia reperfusion-induced injury in rats involvesNrf-2/HO-1 pathway. Pharmacol Rep, 2019, 71(6):1044-1049.
[19] Qu B, Xing R, Wang H,et al. Multiple effects of magnesium isoglycyrrhizinate on the disposition of docetaxel in docetaxel-induced liver injury. Xenobiotica, 2017, 47(4):290-296.
[20] Sui M, Jiang X, Chen J,et al. Magnesium isoglycyrrhizinate ameliorates liver fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway. Biomed Pharmacother, 2018, 106(1):125-133.
[21] Wang W, Li X, Xu J. Magnesium isoglycyrrhizinate attenuatesD-galactosamine/lipopolysaccharides induced acute liver injury of rat via regulation of the P38-MAPK and NF-κB signaling pathways. Immunopharmacol Immunotoxicol, 2018, 40(3):262-267.